AbbVie Inc. (ABBV) — closed signal from October 19, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 17, 2026.
Predicted vs. what happened
What happened
Reached 42% of the predicted growth at its peak, without hitting the target.
The thesis — published October 19, 2025
AbbVie has slid for several days but is showing signs of a short-term bounce as interest improves. The company confirmed buying bretisilocin, a mid-stage depression drug, which adds a new option to its future product lineup. Because the core picture is mixed, this is a quick trade idea, not a long-term upgrade. Over the next 0-3 months, the price could drift back toward its recent average if buying keeps building.
Primary drivers
- Stock fell hard and may rebound soon as short-term pressure eases.
- New drug buy (bretisilocin) adds a potential future product in depression.
- Investor mood is fairly positive even though the core numbers are mixed.
- Stock is usually steadier, which can help it hold up when markets swing.
How it played out
ABBV: target was not reached
Lyra published ABBV at 229.57 on 2025-10-19 as a short-term bounce idea. The thesis expected 10% growth and pointed to eased short-term selling pressure, interest improving, the bretisilocin drug buy, fairly positive investor mood, and the stock's usual steadiness. It also said the core picture was mixed, so this was framed as a quick trade idea.
Inside the window, ABBV rose to a 239.29 peak on 2025-11-13, a 4.2% gain. That stayed below the 252.53 target. The target was never reached. By 2026-01-17, the stock ended at 214.35. The bounce partly showed up, but the full thesis missed.
What happened during the window
On 2025-10-31, AbbVie reported third-quarter results, including 15.78 billion in revenue and adjusted earnings of 1.86 per share. On 2026-01-13, AbbVie struck a deal with the Trump administration to invest 100 billion in U.S. operations and lower Medicaid prices.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.